The estimated Net Worth of Donald J Jr Hayden is at least $2.74 Milion dollars as of 10 February 2020. Donald Hayden owns over 24,800 units of Regenxbio Inc stock worth over $315,208 and over the last 16 years Donald sold RGNX stock worth over $2,427,825.
Donald has made over 26 trades of the Regenxbio Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Donald exercised 24,800 units of RGNX stock worth $21,080 on 10 February 2020.
The largest trade Donald's ever made was exercising 55,000 units of Regenxbio Inc stock on 23 June 2015 worth over $770,550. On average, Donald trades about 8,622 units every 58 days since 2008. As of 10 February 2020 Donald still owns at least 24,800 units of Regenxbio Inc stock.
You can see the complete history of Donald Hayden stock trades at the bottom of the page.
Donald's mailing address filed with the SEC is C/O REGENXBIO INC., 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE, MD, 20850.
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas a Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
Regenxbio Inc executives and other stock owners filed with the SEC include: